Financial News
DateTitlemore >
Jul. 31, 2008Amgen Licenses Molecule for the Treatment of Chronic and Neuropathic Pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Jul. 30, 2008Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today
Jul. 28, 2008Amgen's Second Quarter 2008 Adjusted Earnings Per Share Increased 2 Percent to $1.14
Jul. 25, 2008Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
Jul. 21, 2008250 Amgen Scholars from 10 Premier Universities Convene for National Summer Symposium to Explore Drug Discovery & Development
Jul. 17, 2008Amgen Announces Webcast of 2008 Second Quarter Financial Results
Related Links Stock Quote


AMGN: NASDAQ
$63.86

 (Minimum 20 minute delay)